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Safety in Nonhuman Primates of Ocular AAV2-RPE65, a Candidate
Treatment for Blindness in Leber Congenital Amaurosis
Abstract
Leber congenital amaurosis (LCA) is a molecularly heterogeneous disease group that leads to blindness. LCA
caused by RPE65 mutations has been studied in animal models and vision has been restored by subretinal
delivery of AAV- RPE65 vector. Human ocular gene transfer trials are being considered. Our safety studies of
subretinal AAV-2/2. RPE65 in RPE65 -mutant dogs showed evidence of modest photoreceptor loss in the
injection region in some animals at higher vector doses. We now test the hypothesis that there can be vector-
related toxicity to the normal monkey, with its human-like retina. Good Laboratory Practice safety studies
following single intraocular injections of AAV-2/2. RPE65 in normal cynomolgus monkeys were performed
for 1-week and 3-month durations. Systemic toxicity was not identified. Ocular-specific studies included
clinical examinations, electroretinography, and retinal histopathology. Signs of ocular inflammation
postinjection had almost disappeared by 1 week. At 3 months, electroretinography in vector-injected eyes was
no different than in vehicle-injected control eyes or compared with presurgical recordings. Healed sites of
retinal perforation from subretinal injections were noted clinically and by histopathology. Foveal architecture
in subretinally injected eyes, vector or vehicle, could be abnormal. Morphometry of central retina showed no
photoreceptor layer thickness abnormalities occurring in a dose-dependent manner. Vector sequences were
present in the injected retina, vitreous, and optic nerve at 1 week but not consistently in the brain. At 3
months, there were no vector sequences in optic nerve and brain. The results allow for consideration of an
upper range for no observed adverse effect level in future human trials of subretinal AAV-2/2. RPE65. The
potential value of foveal treatment for LCA and other retinal degenerations warrants further research into how
to achieve gene transfer without retinal injury from surgical detachment of the retina.
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Safety in Nonhuman Primates of Ocular AAV2-RPE65, 
a Candidate Treatment for Blindness in Leber 
Congenital Amaurosis
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ABSTRACT
Leber congenital amaurosis (LCA) is a molecularly heterogeneous disease group that leads to blindness. LCA
caused by RPE65 mutations has been studied in animal models and vision has been restored by subretinal de-
livery of AAV-RPE65 vector. Human ocular gene transfer trials are being considered. Our safety studies of
subretinal AAV-2/2.RPE65 in RPE65-mutant dogs showed evidence of modest photoreceptor loss in the in-
jection region in some animals at higher vector doses. We now test the hypothesis that there can be vector-
related toxicity to the normal monkey, with its human-like retina. Good Laboratory Practice safety studies
following single intraocular injections of AAV-2/2.RPE65 in normal cynomolgus monkeys were performed for
1-week and 3-month durations. Systemic toxicity was not identified. Ocular-specific studies included clinical
examinations, electroretinography, and retinal histopathology. Signs of ocular inflammation postinjection had
almost disappeared by 1 week. At 3 months, electroretinography in vector-injected eyes was no different than
in vehicle-injected control eyes or compared with presurgical recordings. Healed sites of retinal perforation
from subretinal injections were noted clinically and by histopathology. Foveal architecture in subretinally in-
jected eyes, vector or vehicle, could be abnormal. Morphometry of central retina showed no photoreceptor
layer thickness abnormalities occurring in a dose-dependent manner. Vector sequences were present in the
injected retina, vitreous, and optic nerve at 1 week but not consistently in the brain. At 3 months, there were
no vector sequences in optic nerve and brain. The results allow for consideration of an upper range for no
observed adverse effect level in future human trials of subretinal AAV-2/2.RPE65. The potential value of
foveal treatment for LCA and other retinal degenerations warrants further research into how to achieve gene
transfer without retinal injury from surgical detachment of the retina.
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OVERVIEW SUMMARY
Ocular gene therapy has emerged as a potential treatment
modality for many incurable human genetic retinal diseases.
As preclinical evidence of success mounts, the need for
translational research increases. An autosomal recessive
retinal blindness caused by a defect in the retinoid (visual)
cycle, Leber congenital amaurosis caused by RPE65 gene
mutations, has become the target disease for a number of
groups worldwide for the first subretinal gene transfer trial
in man. The present paper builds on the substantial foun-
dation of dog and rodent proof-of-concept, dose efficacy,
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and safety data with rAAV-2/2.RPE65. Questions about sys-
temic and retinal toxicity are asked in a nonhuman primate,
the only mammal with a foveate retina like that of humans,
to determine whether there is sufficient safety to initiate hu-
man clinical trials.
INTRODUCTION
LEBER CONGENITAL AMAUROSIS (LCA) is the clinical diag-nosis given to a group of early-onset retinal blinding dis-
eases caused by mutations in many different genes (Cremers
et al., 2002; Preising and Heegaard, 2004). Naturally occur-
ring and genetically engineered animal models of a number
of the molecular forms of LCA have been studied. Animal
models of three different forms have already been success-
fully treated with ocular gene transfer by subretinal injection
(e.g., Acland et al., 2001; Batten et al., 2005; Pawlyk et al.,
2005).
The largest amount of preclinical data assembled to date
has been on the form of LCA due to mutations in the RPE65
gene. RPE65 is the isomerohydrolase in the retinal pigment
epithelium (RPE) cells and it catalyzes the critical step in
the visual cycle converting all-trans-retinyl ester to 11-cis-
retinol and permitting normal photoreceptor function and vi-
sion to occur (Redmond et al., 1998, 2005; Rando, 2001;
Thompson and Gal, 2003; Jin et al., 2005; Moiseyev et al.,
2005). Restoration of vision to blind eyes of large and small
animals with RPE65 deficiency has occurred by subretinal
delivery of RPE65-expressing recombinant adeno-associated
virus (rAAV)-based vector (Acland et al., 2001, 2005; Narf-
strom et al., 2003; Dejneka et al., 2004; Lai et al., 2004; Ja-
cobson et al., 2005; Pang et al., 2006). The relationship of
the phenotype in the animal models to that in the human reti-
nal disease caused by RPE65 mutations was found to be sim-
ilar enough to justify consideration of a clinical trial 
(Jacobson et al., 2005). Dose efficacy of subretinal rAAV-
2/2.RPE65 in RPE65-mutant dogs was also determined and
the highest 1.5 log units of vector doses used were effica-
cious (Jacobson et al., 2006). Safety studies in these dogs
and investigations in normal rats showed no evidence of sys-
temic toxicity. Localized retinal toxicity evident by ocular
histopathology, however, was observed in the dogs and it
was postulated to have a vector dose-independent component
due to surgical trauma and a vector dose-related thinning of
the outer retina. The latter was present in some but not all
dogs that received the two highest vector doses used (Ja-
cobson et al., 2006).
The present work examines safety of subretinal rAAV-
2/2.RPE65, specifically with the two highest vector doses, in
normal nonhuman primates. The importance of these experi-
ments in the scheme of preclinical investigations is that the
monkey retina is human-like in organization and, unlike other
mammals, the monkey shares with humans a specialized cen-
tral region of high cone photoreceptor density known as the
fovea (Polyak, 1941; Curcio et al., 1990; Provis et al., 2005).
A short-term (1-week) study of 6 monkeys and a longer term
(3-month) study of 11 monkeys after ocular gene transfer to the
central retina were performed and systemic and ocular toxicity
was evaluated.
MATERIALS AND METHODS
Animals and ocular surgery
Normal cynomolgus monkeys (n  17; age, approximately 2
years; weights, 1.8–2.6 kg) were studied under Good Laboratory
Practice (GLP)-compliant protocols. The ocular surgical proce-
dures for subretinal and intravitreal injections were performed
with sterile instruments, surgical fields, and solutions; methods
were similar to previously described work (Bennett et al., 1999)
except that three sclerotomy incisions were made. A lid specu-
lum was placed and a radial conjunctival peritomy incision was
made in the right-hand superior quadrant. The pars plana region
sclerotomy site was marked on the external sclera. Three separate
27-gauge sclerotomy incisions were made in the following loca-
tions: in the bed of the prepared sclera (right-hand superior quad-
rant), in the opposite (left-hand superior) quadrant, and in the in-
ferotemporal quadrant. An anterior chamber paracentesis was
performed with a 30-gauge needle introduced via the limbal
cornea. A sterile contact lens coupling solution was applied to the
corneal surface. A sterile Machemer fundus contact lens was then
placed into position. Using coaxial illumination and direct visu-
alization through an operating microscope, the shaft of the sub-
retinal injector was introduced through the right-handed superior
quadrant sclerotomy into the midvitreous cavity. An extendable
41-gauge cannula was positioned so that it was apposed to the
retinal surface at an oblique angle. The retina was draped over the
cannula tip; the retinal surface was penetrated, avoiding injury to
the RPE and choroid. Test article or vehicle was injected to con-
firm that the tip was not occluded and was properly positioned.
If necessary, it was repositioned. The remaining volume of the
test article or vehicle was injected to achieve the total volume.
The injector was removed. All studies were in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research (Association for Research in Vision and Oph-
thalmology, Rockville, MD) and institutional approval.
rAAV-RPE65 vector production, purification, 
and characterization
Details of the production, purification, and characterization
have been published (Jacobson et al., 2006).
Clinical assessments
Mortality and clinical observation. The animals were ob-
served on a daily basis with attention to signs of change in be-
havior/activity, food consumption, fecal/urinary output, general
habits, and skin/hair changes. Weights were obtained weekly
and at termination.
Ophthalmic examinations. Monkeys had ophthalmic exami-
nations before dosing, at 1 day, 1 week, and then at 1, 2, and
3 months postinjection. The examinations included slit lamp
biomicroscopy, indirect ophthalmoscopy, and measurement of
intraocular pressure (Tono-Pen Vet; Medtronic Ophthalmics,
Jacksonville, FL).
Electroretinography
Monkeys (n  11) had full field bilateral simultaneous elec-
troretinograms (ERGs) before and 3 months after ocular sur-
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gery; protocols conformed to the International Society for Clin-
ical Electrophysiology of Vision standards for human ERG
recordings (Marmor et al., 2004). Animals were dark-adapted
for 3 hr before testing. Anesthesia, given under dim red light,
was with intramuscular ketamine-HCl (10 mg/kg) and xylazine
(0.5 mg/kg). Corneas were anesthetized with topical propara-
caine-HCl (1%) and pupils were dilated (6–8 mm diameter)
with topical tropicamide (1%) and phenylephrine (10%). Body
temperature was maintained with an electric heating pad.
Recordings were performed with a computer-based system (Di-
agnosys, Littleton, MA). Burian–Allen bipolar contact lens
electrodes (Hansen Ophthalmic, Coralville, IA) were used. The
protocol is similar to a previously published protocol used for
human studies (Jacobson et al., 1989, 1995) and included re-
sponses under four conditions, two dark-adapted and two light-
adapted. A dark-adapted rod ERG b-wave was obtained with a
0.025 (scotopic) cd  sec  m–2 blue flash. A dark-adapted,
mixed cone and rod ERG was elicited with a standard white
flash of 5.77 (photopic) cd  sec  m–2. After this, a light-adapt-
ing white background of 34 (photopic) cd  m–2 was presented
for 5 min. Cone ERGs were then recorded with the standard
white flash presented at 1 Hz on the same background, and with
29-Hz flicker on a 6.9 (photopic) cd  m–2 white background.
A- and b-wave amplitudes and timing were quantified conven-
tionally (Jacobson et al., 1989, 1995). Light level calibrations
were performed before test sessions, using an integrating pho-
tometer with photopic and scotopic filters (IL1700; Interna-
tional Light, Peabody, MA). Acquisition stage amplitude and
timing calibration were verified externally before the sessions,
using a calibration device (2506; LKC Technologies, Gaithers-
burg, MD). Differences between sessions for each eye, and be-
tween eyes for each session were compared on the basis of
paired t tests.
Clinical pathology
Serum chemistry, hematology. Peripheral venous blood was
collected for hematology and serum chemistry. Hematology pa-
rameters included red blood cell count and morphology, he-
moglobin, hematocrit, and white blood cell and platelet counts.
Serum chemistries included blood urea nitrogen, creatinine, ala-
nine aminotransferase, aspartate aminotransferase, alkaline
phosphatase, bilirubin, total protein, albumin, globulin, cal-
cium, sodium, potassium, chloride, glucose, total iron, choles-
terol, and triglycerides.
Anti-AAV2 antibody assays. Serum samples from the mon-
keys receiving either a subretinal or intravitreal injection of vec-
tor were assayed for circulating antibodies to the AAV2 capsid
proteins. For the 1-week study, serum samples were collected
on days 0, 2, and 8. For the 3-month study, sera were collected
on days 0, 8, 30, and 90 postinjection. Briefly, 96-well plates
were coated with 1.2  109 AAV2 particles/well overnight at
4°C. A wash with phosphate-buffered saline (PBS)–Tween was
followed by blocking for 2 hr at 37°C with 10% fetal bovine
serum (Cellgro; Mediatech, Herndon, VA). After a 1 wash
with PBS–Tween, samples and a known positive human stan-
dard were diluted between 1:10 and 1:10,240 and allowed to
bind overnight at 4°C. Each sample was run in triplicate. Wash-
ing was followed by addition of the detection antibody at a di-
lution of 1:50,000 (goat anti-human immunoglobulin, conju-
gated with horseradish peroxidase [HRP]; Biosource Interna-
tional, Camarillo, CA) for 2 hr at 37°C. Finally, the plate was
washed and exposed to tetramethylbenzidine (TMB) peroxidase
detection substrate (KPL, Gaithersburg, MD) and read at 
450 nm with an enzyme-linked immunosorbent assay (ELISA) 
plate reader (Molecular Devices, Sunnyvale, CA). Sample anti-
AAV2 titers were then read relative to a human standard curve
derived from the same plate.
Necropsy and histopathology
A complete gross necropsy was performed and non-ocular
tissues were sampled for histopathology in both 1-week and 3-
month studies. Slides from nonocular tissues were prepared and
interpreted by Charles River Laboratories, Preclinical Services,
Pathology Associates (Chicago, IL).
Ocular tissue handling at necropsy in the two studies. An
emphasis of the longer duration study on quantitative ocular
histopathology led to some differences in procedure between
the 1-week and 3-month studies (detailed below).
Study I (duration, 1 week): At necropsy, the eyes were enu-
cleated. The anterior segment was removed and divided for
biodistribution and histopathology studies. When tissues were
collected for biodistribution, appropriate precautions were taken
to avoid cross-contamination. The eyecup was cut vertically
through the region of subretinal injection (guided by fundus
drawings of the animals). The calotte including the fovea and
optic nerve was designated for histopathology (immersion fixed
in Bouin’s solution). For the remaining and more temporal
calotte, retina was separated from the RPE–choroid–sclera and
submitted for biodistribution studies. A vitreous sample and the
optic nerve tissue proximal to the globe were also used for
biodistribution studies. The remaining intraorbital optic nerve
was designated for histopathology. Regions of the brain, with
special attention paid to the visual pathways, were dissected
and submitted as paired samples: one for biodistribution and
one for histopathology.
Study II (duration, 3 months): At necropsy, the eyes were
enucleated and the optic nerve was removed at the point at
which it exits the globe. The optic nerve most proximal to the
globe was used for biodistribution studies and the remainder of
the intraorbital optic nerve was designated for histopathology.
The intact globe was immersion fixed in Bouin’s solution for
histopathology. As with the 1-week study, regions of the brain
with attention to the visual pathways were dissected and sub-
mitted as paired samples: one for biodistribution and one for
histopathology.
Ocular histopathology. Histological examination was per-
formed on 5-m paraffin-embedded sections stained with
hematoxylin and eosin. Unstained sections were studied by im-
munocytochemistry in study II only. Preparation of slides of
ocular tissues was performed by Research Pathology Services
(Doylestown, PA). Details of how the eyes were divided for
sectioning are as follows.
Study I (duration, 1 week): Sections were examined from the
optic nerve, anterior segment, superior temporal retina (site of
subretinal injection in six eyes), inferior temporal retina, and
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nasal retina. All retinal sections were from the portion of the
eyecup designated for histopathology (see above). The tissue
was first divided by a vertical cut nasal to the optic nerve, leav-
ing a calotte that included the fovea (and superior injection re-
gion in right eyes) and optic nerve, and a second calotte of nasal
retina. The more temporal calotte was then divided into two
blocks by a horizontal cut inferior to the fovea (leaving the su-
perior temporal region that included the injection site and an
inferior temporal region). The remaining nasal calotte was not
further divided.
Study II (duration, 3 months): The intact globe was divided
using two vertical cuts: one nasal to the optic nerve (about 2
mm) and one temporal to the fovea (about 4 mm temporal to
the optic nerve). Sections were taken from the resulting three
calottes (described as central, temporal, and nasal). The central
calotte (including fovea and superior injection region and cor-
responding inferior region) was cut toward the nasal retina un-
til the foveal depression was identified. The temporal calotte
(including part of injection region) was cut further into the tem-
poral retina. The nasal calotte was cut further into the nasal
retina.
Morphometry in study II. Vertical sections from the central
calotte that crossed near the foveal depression, and from the
temporal and nasal calottes, were used for morphometry using
methods and strategy as in previous work (e.g., La Vail et al.,
2000; Hare et al., 2004; Leung et al., 2005). Contiguous fields,
extending from the central retina into the far superior and in-
ferior retina, were imaged at 10 magnification with a camera
(Olympus BH2; Olympus America, Melville, NY) attached to
a microscope (Leica DFC480; Leica Microsystems, Bannock-
burn, IL). At least 60 viewing field images extending from the
centralmost retina into the superior and inferior retina were dig-
itized, scaled with a calibration tool (Graticules, Tonbridge,
Kent, UK) and montaged with image-editing software (Adobe
Photoshop 6.0; Adobe Systems, San Jose, CA). Measurements
were made on montaged images with imaging software (Spot
4.0.9; Diagnostic Instruments, Sterling Heights, MI). Outer nu-
clear layer (ONL) thickness was measured at 500-m intervals.
ONL thickness results for the untreated left eyes (LEs) were
compared with results from vehicle-injected or vector-injected
right eye (RE) samples.
Immunocytochemistry was performed as previously de-
scribed (Acland et al., 2005). Slides from vertical sections of
each eye were incubated with RPE65 PETLET antibody (di-
luted 1:5000; gift of T.M. Redmond, Laboratory of Retinal Cell
and Molecular Biology, National Eye Institute, National Insti-
tutes of Health, Bethesda, MD). Negative controls were serial
sections of the positive slides and were incubated with the pri-
mary antibody omitted.
Vector biodistribution
Procedures for biodistribution studies have been described
(Song et al., 2002; Jacobson et al., 2006). In brief, 1 g of ex-
tracted genomic DNA was used in all quantitative polymerase
chain reactions (PCRs); reaction conditions followed those rec-
ommended by PerkinElmer/Applied Biosystems (Foster City,
CA) and included 50 cycles of 94°C for 40 sec, 37°C for 2 min,
55°C for 4 min, and 68°C for 30 sec. Primer pairs were de-
signed to the cytomegalovirus (CMV) enhancer/chicken -actin
promoter as described (Donsante et al., 2001) and standard
curves were established by spike-in concentrations of a plas-
mid DNA (CBAT) carrying the same promoter as above and
the 1-antitrypsin cDNA (Song et al., 2002). DNA samples
were assayed in triplicate. The third replicate was spiked with
CBAT DNA at a ratio of 100 copies/g of genomic DNA. If
at least 40 copies of the spike-in DNA were detected, the DNA
sample was considered acceptable for reporting vector DNA
copies. When the copy number of the vector DNA found in that
sample was 100 copies/g, the sample was considered posi-
tive and the measured copy number per microgram was re-
ported. The sample was considered negative if 100 copies/g
were present. When 1 g of genomic DNA was analyzed to
avoid PCR inhibitors copurifying with DNA in the extracted
tissue, the spike-in copy number was reduced proportionally to
maintain the 100 copies/g DNA ratio.
RESULTS
Two studies of different durations in nonhuman primates
(Table 1) were performed to determine the safety of intraocu-
lar injections of rAAV-2/2.RPE65. The vector used in both
studies is denoted as rAAV2-CBSB-hRPE65 (Jacobson et al.,
2006). Sequencing of the plasmid DNA used to make the vec-
tor confirmed that it contained two AAV2 inverted terminal re-
peats that surround a regulatory element composed of the CMV
immediate-early enhancer, chicken -actin promoter with first
intron/exon junction, hybrid chicken -actin, and rabbit -glo-
bin intron/exon junction, followed by a human RPE65 cDNA,
and the simian virus 40 (SV40) polyadenylation signal. In both
studies, right eyes (REs) received a single intraocular injection
and left eyes (LEs) served as controls. All subretinal (SR) in-
jections were in the superior posterior retina (Fig. 1). The re-
sults of clinical systemic and ocular examinations and clinical
pathology of both 1-week and 3-month studies are presented
together; results of pathology and vector biodistribution are pre-
sented individually for the two studies.
Mortality, clinical observations, and clinical pathology
Monkeys with ocular injections of rAAV-2/2.RPE65 or ve-
hicle control remained clinically healthy for the duration of the
experiments. There were no early deaths and no clinical signs
of toxicity noted during the study. There were no test article-
related effects on food consumption and no changes in body
weight. There were also no test article-related changes in hema-
tology or clinical chemistry parameters.
Ocular examinations
In vivo assessments of preretinal ocular structures at four
time points postinjection are summarized in Fig. 2 for the 17
monkeys. Abnormalities were graded at three levels of sever-
ity. After mild conjunctival reactions at 1 day in 6 of the 17
monkeys, there was no clinical evidence of conjunctival ab-
normality at 1 week postinjection. Corneal changes, specifically
mild punctate keratopathy in the inferior cornea, were present
at both time points. Anterior chamber flare (scored as mild) was
noted in six monkeys (all vector treated) at 1 day and in only
JACOBSON ET AL.848
two monkeys (including one vehicle control) at 1 week. Mild
lens changes were noted in one vector-treated (intravitreal)
monkey at 1 day (mild posterior capsular opacity) and in two
vector-treated (subretinal) monkeys at 1 week (mild anterior
capsular opacity, possibly related to the paracentesis proce-
dure). Vitreous cells were seen in three of five vehicle control
eyes at 1 day and in two vector-treated eyes at 1 week. By 2
months, there were no detectable abnormalities and this was
also the case at 3 months after surgery.
Funduscopic abnormalities at 1 day after surgery in eyes with
subretinal injections showed mainly persistence of elevated
retina, and small intraretinal hemorrhage and RPE changes at
or near the retinotomy site. Surrounding uninjected retina was
normal in appearance. By 1 week, many of the eyes showed ei-
ther flattening of the retina or less prominent elevations. The
region of initially injected retina, even if no longer elevated,
appeared discolored and demarcated from surrounding unin-
jected retina. Examinations 1, 2, and 3 months after surgery re-
vealed persistent RPE changes or atrophic scars at or near the
retinotomy site and demarcation lines between injected and un-
injected retina. There was no distinguishable difference between
vehicle-injected or vector-injected eyes in the prominence of
such findings. Eyes with intravitreal injections had normal-
appearing fundi.
Retinal electrophysiology
Retinal toxicity was evaluated by electroretinography
(ERG). ERGs were performed pre- and 3 months posttreat-
ment in both eyes of the 11 monkeys in study II (Fig. 3). Rep-
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TABLE 1. CHARACTERISTICS OF NONHUMAN PRIMATES AND OCULAR DOSES OF
rAAV2-CBSB-hRPE65 INJECTED
Injection Vector dose Vector genomes
Animal (no.) Gender route (relative)a delivered (1010)a
Study I (1 week)
M1 (20515) F SR 0 000
M2 (20564) M SR 0 000
M3 (20507) F SR 1 150
M4 (20566) M SR 1 150
M5 (20480) F SR 3 300
M6 (20552) M SR 3 330
Study II (3 months)
M7 (20877) M SR 0 000
M8 (20547) M SR 0 000
M9 (C06987) F SR 0 000
M10 (20730) M SR 1 150
M11 (C06992) F SR 1 150
M12 (C08913) F SR 1 150
M13 (20777) M SR 3 450
M14 (20732) M SR 3 450
M15 (C09033) F SR 3 450
M16 (20725) M IV 1 150
M17 (20747) M IV 3 450
Abbreviations: SR, subretinal; IV, intravitreal.
a0, vehicle injected; 1, 1.0  1010 vg/l (injections were 150 l in volume, except in M5, 100
l; M6, 110 l).
FIG. 1. Drawings of the ophthalmoscopic ap-
pearance of the monkey retina (right eye) and the
superior central sites of the subretinal injections
of vehicle control (A) and vector (B). , foveal
location.
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FIG. 2. Ocular examination results at five time points spanning 3 months in monkeys after delivery of rAAV-2/2.RPE65 (cir-
cles and squares) compared with vehicle control (open diamonds). Inflammatory changes (conjunctival hyperemia, chemosis, or
discharge; cellularity/precipitates in anterior chamber and/or vitreous) as well as changes in transparency of ocular media
(cornea/lens/vitreous) were assessed by slit lamp biomicroscopy and indirect ophthalmoscopy. Clinical changes were graded at
three levels of severity. Results from individual eyes are presented from left to right in order of increasing relative vector dose
levels; data points are arbitrarily offset in the vertical direction within each dose level and ocular evaluation category. The two
vector doses are represented by gray (1) and black (3) in the symbols (scale at bottom right).
resentative waveforms using four stimulus conditions in mon-
key 14 (M14) (subretinal, 3 dose in RE) illustrate that there
were no dramatic interocular differences (IODs) posttreat-
ment (Fig. 3B), compared with the pretreatment recordings
(Fig. 3A). By inspection, the results in all 11 monkeys showed
no dramatic IOD. Quantitative comparisons of intervisit vari-
ation and IODs for five amplitude parameters are also pro-
vided (Fig. 3C). Treated eyes (REs) and untreated eyes (LEs)
showed similar intervisit variation for all measured parame-
ters; there were no statistically significant differences be-
tween eyes for the parameters tested, regardless of vector
dose (p  0.5 for all comparisons). The standard deviations
for intervisit differences (posttreatment minus pretreatment)
in amplitude parameters (in microvolts) for untreated eyes
were as follows: rod b-wave, 22.2; mixed a-wave, 23.5;
mixed b-wave, 41.5; cone single-flash b-wave, 21.5; and cone
flicker, 25.6. For IOD, we found no significant difference
(p  0.6 for all comparisons) when measured at pre- or post-
treatment sessions. This was true for all vector-treated eyes.
The standard deviations for IOD in amplitude parameters (in
microvolts) for pretreatment recordings were as follows: rod,
17.2; mixed a-wave, 17.2; mixed b-wave, 24.4; cone single-
flash b-wave, 8.5; and cone flicker, 8.7.
Anti-AAV2 antibody assays
Circulating antibodies to AAV2 capsid proteins were assayed
by ELISA from collected serum samples. In the 1-week study,
serum samples were assayed from days 0, 2, and 8 postinjec-
tion. Antibody titers were calculated relative to serial dilution
of a positive anti-AAV2 human serum run simultaneously. For
all animals, the antibody titers were low before treatment
(range, 5.7–53.7 mU/ml) and remained so for the study dura-
tion. In the 3-month study, serum samples were assayed from
days 0, 8, 30, and 90 postinjection. Although pretreatment lev-
els ranged from 3471 to 406,556 mU/ml, suggesting many an-
imals had substantial preexisting anti-AAV2 antibodies, there
was no consistent increase or decrease over the 3-month period
after vector administration as a function of either vector dose
or site of injection.
Pathology and vector biodistribution: study I
Necropsy and non-ocular histopathology. There were no
gross necropsy findings noted at termination of the study. There
were no test article-related changes in organ weights. Mi-
croscopy showed minimal chronic inflammation of the heart in
five of six monkeys, including M1 (SR vehicle control injec-
tion); the exception was M2, the other SR vehicle-injected mon-
key. No microscopic lesions were considered to be related to
administration of the test article; and all microscopic findings
were interpreted as incidental findings commonly present in
nonhuman primate toxicology studies.
Ocular histopathology. Anterior segments of all eyes were
abnormal because of postmortem processing (bisection of eyes)
in order to share tissue for histology and biodistribution stud-
ies. The optic nerves had no lesions except in the RE of M1
and M2 (both vehicle controls), in which there were subtle vac-
uoles containing macrophages.
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FIG. 3. Retinal function before and
after unilateral (RE) subretinal injec-
tions in monkeys. Representative ERG
tracings (M14) before (A) and 3 months
after (B) RE subretinal injection of the
vector. Dark-adapted rod and mixed
cone–rod ERGs, and light-adapted cone
ERGs to 1- and 29-Hz flicker are
shown. Stimulus onset is at trace onset
or denoted by vertical gray bars in 29-
Hz responses. Calibration bars are at
bottom right of waveforms. (C) Com-
parison of ERG amplitudes between
treated eyes (diamonds, vehicle control;
circles, two different doses of rAAV-
2/2.RPE65) and untreated eyes
(squares). First row: intervisit differ-
ences (posttreatment minus pretreat-
ment) in treated and untreated eyes.
Dashed lines represent means 	 2 SD
of the intervisit differences for the un-
treated eyes; dotted line indicates zero.
Second row: interocular differences
(RE minus LE) measured at pre- and
posttreatment sessions. Dashed lines
represent means 	 2 SD of the interoc-
ular differences pretreatment; dotted
line indicates zero difference.
Retinal sections were taken vertically through the temporal
retinal region of subretinally injected REs and in a comparable
location in the LEs. A nasal retinal section was also taken from
each eye. There was no evidence of necrosis, inflammation, cell
proliferation, or extensive hemorrhage in any of the eyes. Patho-
logical changes were definitely present in the REs of all six an-
imals. Retinal perforation with detachment, presumably from
the subretinal injection, was identified in the superior posterior
temporal retina of the RE of all animals. These detachments
were accompanied by clusters of glial cells, melanophages, and
retinal pigment epithelium (RPE) cells. In addition, nuclear
fragments of dying photoreceptor cells appeared to be present.
The inferior temporal retina and nasal retina had no perforation
sites, as anticipated from fundus drawings of the site of injec-
tion (Fig. 1), but artifactual detachment due to postmortem pro-
cessing was present in most sections.
Biodistribution. Vector biodistribution was studied in ocular
tissues and other organs of six monkeys (Table 2). Vector DNA
was detectable in two different non-ocular, non-CNS tissues at
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TABLE 2. DETECTION OF rAAV VECTOR SEQUENCES BY PCR IN NONHUMAN
PRIMATE TISSUE SAMPLES: STUDY I, ONE-WEEK DURATION
M1a M2 M3 M4 M5 M6
0b/SRc 0/SR 1/SR 1/SR 3/SR 3/SR
Non-ocular tissues
Heart — — na — — —
Lung na na na na na —
Liver — — — na — —
Pancreas — — — — — —
Spleen na na — — — —
Kidney — na na — na —
Jejunum — — na — — —
Gonads — — — — — —
Skeletal muscle — — (152) (3,781) — —
Lymph nodes
Preauricular — na — 	(180) — na
Mandibular — — na — — —
Tracheobronchial — — — — — —
Mesenteric na na na — — —
Eye and orbit (L)
Vitreous (L) nd — na — nd nd
Retina (L) — — — — — —
Optic nerve (L) — na na — — na
Orbital tissue (L) na — na — na na
Eye and orbit (R)
Vitreous (R) — na (6,545) (25,565) (920,700) nd
Retina (R) — — (2,930,674) (436,307) (470,375) (2,459,501)
Optic nerve (R) na — (601) (127) (1,360) (665)
Orbital tissue (R) — — na — — na
Optic chiasm — — — — — —
Visual pathways (L brain)
Optic tract (L) — (124) — (439) 	(106) —
LGN (L) — — — — — —
Visual cortex (L) — — — — (200) —
Superior colliculus (L) — — — — — (184)
Visual pathways (R brain)
Optic tract (R) — na — 	(155) (114) (264)
LGN (R) — — — 	(144) 	(123) —
Visual cortex (R) — na — — — —
Superior colliculus (R) na na — — — —
Brain samples (other)
Thalamus (L) — — — — — —
Thalamus (R) — — na — — —
Cerebellum — — na — na na
Abbreviations: L, left; R, right; —, no PCR amplification; PCR amplification of vector sequences:  (replicated value shown
is average, copy number per microgram of genomic DNA); 	 (single replicate value only, copy number per microgram of ge-
nomic DNA); na, not available (not determinable because of an unacceptable spike-in); nd, not done; LGN, lateral geniculate 
nucleus.
aAnimal no.
bVector dose, relative per Table 1.
cRoute of ocular delivery, subretinal (SR).
100 single-stranded DNA copies per microgram of genomic
DNA. M3 and M4, the two monkeys with subretinal 1 dose,
both showed positive and replicated results for the skeletal mus-
cle sample (thigh). M4 also had a single value (that did not
replicate on retest) in the preauricular node sample. M5 and
M6, representing higher doses, did not show vector sequences
in these tissues, making the significance of the 1 dose results
uncertain. All gonadal samples were negative for vector se-
quences. Both vector-dosed groups had positive and replicated
results in the vector-injected RE: retina, vitreous, and optic
nerve. The uninjected LE tissues were negative for vector se-
quences, as were both LE and RE orbital tissue samples. The
optic chiasm was negative in all vector-dosed animals. Of the
32 further samples from the visual pathways in vector-dosed
monkeys, there were 5 positive and replicated results and 4 re-
sults with vector sequences in only one of the two replicate PCR
determinations (Table 2). Most of these positive results in the
visual pathways of these monkeys were just above the 100-copy
minimum reportable value. M3, an animal with a 1 dose, had
no vector sequences in the visual brain. Other brain samples
(thalamus and cerebellum) were negative in all monkeys. The
results suggest that 1 week after subretinal vector delivery, there
is only sporadic and limited vector DNA detectable outside of
the injected eye and optic nerve.
Pathology and vector biodistribution: study II
Necropsy and non-ocular histopathology. No gross necropsy
findings were noted at termination of the study. There were no
test article-related changes in organ weights. Mild chronic in-
flammation of the heart was noted in M15, the only female
monkey that received a subretinal 3 vector dose. The only fe-
male vehicle control (M9) did not show this result. There was
also a low level of chronic inflammation of the kidneys in some
of the monkeys, but this level is commonly present in primate
kidneys and not considered vector dose related (Roberts et al.,
1972; Skelton-Stroud and Glaister, 1987).
Ocular histopathology. Retinotomy sites were identified in
the superior central retina of most eyes with subretinal injec-
tions. These retinal perforations appeared to be healed with no
signs of inflammation. Superior retinal sections from two eyes
with subretinally injected vehicle (M7 and M8) and two eyes
with vector injections (M15 and M13) are illustrated in Fig. 4.
M7 has a healed needle track with disruption of the inner nu-
clear layer (INL) and focal loss of ganglion cells (Fig. 4A). M8,
also with a healed needle track, has focal loss of photorecep-
tors and ganglion cells with mild disorganization of the inner
nuclear layer (Fig. 4B). M15 (3 vector-injected eye) has a
healed needle track with disruption of retinal laminae and mod-
est loss of cells of all layers (Fig. 4C). M13, another 3 vec-
tor-injected eye, has a healed retinal perforation site with all
layers in register but there is focal RPE change, an ONL with
variable thickness, and vacuolar spaces in the INL (Fig. 4D).
The uninjected LEs of all animals showed no such retinal le-
sions. There were no lesions in the optic nerves.
Most central retinal sections were through the fovea and
many were near the foveola (Polyak, 1941; Hogan et al., 1971;
Provis et al., 2005). Foveal anatomy in most of the eyes with
subretinal injections was locally abnormal. Of the three eyes
with vehicle injections, M9 showed some pigment in the sub-
retinal space of the RE (Fig. 4E) that was not evident in the un-
injected LE (Fig. 4F). Two of three eyes with the 1 vector
dose also had subretinal or intraretinal pigmentary disturbances
at the fovea. The most extreme change was in the RE of M10
(Fig. 4G): there was a foveal retinal detachment of about 1 mm
in diameter and thick subretinal tissue composed of fibroblasts,
melanocytes, and possibly RPE cells; both eyes from this ani-
mal shared artifactual fragmentation of the inner retina (Fig. 4G
and H). A small clump of pigment was also present within the
foveal ONL of the RE of M11. The other animal with 1 sub-
retinal injection, M12, showed no such abnormalities in the
fovea of the RE. Two of three animals with a 3 vector dose
injected subretinally had no obvious differences between the
foveal regions of injected and uninjected eyes. ONL and pho-
toreceptor outer segments adjacent to the fovea of the RE of
M14 (Fig. 4I), however, appeared slightly thinner than those of
the LE (Fig. 4J). Such impressions prompted morphometry of
the ONL (see below). Of the two eyes with intravitreal injec-
tions, one had no foveal section available (M16, RE); a section
from the RE of M17 was normal-appearing and not obviously
different from the LE.
Thickness of the ONL was sampled at 2, 4, 6, and 10 mm
eccentric from the central fovea in the superior and inferior
retina of the RE of the nine monkeys with subretinal injections
and in one of two intravitreally injected monkeys (Fig. 5A).
Similar analyses were performed in the temporal retina (Fig.
5B) and nasal retina (Fig. 5C). The uninjected LE of eight of
nine monkeys with RE subretinal injections (M7, LE section
was unavailable) and the uninjected LE of both intravitreally
injected animals served as controls for these ONL measure-
ments. Only the injected eyes of M10 (1 dose) and M14 (3
dose) were reduced in ONL thickness compared with control
eyes. Both M10 and M14 fell outside the normal limits (de-
fined as 2 SD from mean of LE data) at 2 mm in the central
superior retina; M10 was also abnormally reduced at 4 mm su-
periorly. These superior retinal locations were within the in-
jection region. Using a criterion of 3 SD, however, all loci were
within normal limits. Other eyes with 1 and 3 doses were
within the normal limits (Fig. 5A). Temporal retinal ONL thick-
ness measurements were measured and plotted (Fig. 5B); at the
10-mm superior eccentric locus, M9 (vehicle control injection)
showed an abnormally thinned ONL. Nasal retinal measure-
ments in the vertical meridian (nasal to the optic nerve) showed
no ONL thinning in any of the injected eyes.
Immunocytochemical staining of vertical sections through
the central retina showed RPE65 localization only within the
RPE, as expected in these normal animals. Intensity of the
RPE65 label was comparable between all positive slides. Back-
ground/nonspecific labeling was low and negative controls pro-
vided conclusive determination that there was no labeling out-
side the RPE in any of the positive slides.
Biodistribution. Vector biodistribution 3 months after ocular
injection was studied in non-ocular tissues as well as in orbital
tissue, optic nerve, and visual pathways of the 11 monkeys
(Table 3). Unlike in the 1-week study, the eyes were analyzed
exclusively for histopathology (see Materials and Methods,
above). Of the non-ocular tissues, a single positive and repli-
cated result was found in the lung sample of M16 (1, intra-
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vitreal). Otherwise, no vector sequences were detected in non-
ocular tissues or in the orbital samples. All optic nerves from
vector-dosed eyes were negative, as was the optic chiasm from
these animals. Of the 10 samples from the visual pathways of
each of the 9 vector-dosed monkeys, only 1 positive result
(replicated) was found and this was in the left lateral genicu-
late nucleus of M11 (1, subretinal). All gonadal tissue was
negative. The results suggest that 3 months after subretinal and
intravitreal vector delivery, vector DNA is not widely detectable
in non-ocular tissues, including gonads, or in the optic nerve
and other parts of the visual pathways sampled.
DISCUSSION
Gene therapy using recombinant AAV2 is attractive because
of efficient and prolonged transgene expression in target tissues
(reviewed in Couto, 2004; Flotte, 2005). Preclinical intraocu-
lar gene transfer experiments using rAAV2 have increased in
number and there are many successes in animal models of oth-
erwise incurable human retinal diseases (Surace and Auricchio,
2003; Rolling, 2004; Auricchio and Rolling, 2005; Dinculescu
et al., 2005). The next step toward human application of
rAAV2-mediated gene transfer to the retina requires safety data.
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FIG. 4. Ocular histopathology of monkeys 3 months postinjection of rAAV-2/2.RPE65 vector or vehicle. (A–D) Superior cen-
tral retinal locations (subretinal injection site) in the RE of four monkeys. (A and B) Two monkeys (M7 and M8) with vehicle
injections. (C and D) Two monkeys (M15 and M13) with 3 vector injections. (E–J) Foveal histopathology in the RE and LE
of three monkeys. REs are depicted on the left; LEs are on the right. (E and F) M9, a vehicle-injected animal, shows subretinal
pigment (arrow) in the injected RE but not in the LE. (G and H) M10, a 1 vector-injected animal, shows thick pigmented sub-
retinal tissue (arrow) in the injected RE but not in the LE. There is artifactual inner retinal fragmentation in both eyes. (I and J)
M14, a 3 vector-injected animal, shows normal foveal architecture in both eyes but slightly thinner outer retinal layers in the
RE. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
al., 2005). The results in the RPE65-mutant dog showed a range
of efficacious doses, but retinal histopathology at the highest
two doses used suggested modest toxicity in some of the ani-
mals. The current study in the normal nonhuman primate was
undertaken to seek further data on systemic and local ocular ef-
fects of these higher vector doses to define the upper dose limit
in future human trials.
No systemic toxicity was detected in the monkeys after ei-
ther dose of ocular rAAV-2/2.RPE65. Dissemination of vector
to organs distal to the eye after intraocular delivery has now
been investigated in three species using rAAV-2/2.RPE65. Our
biodistribution studies in normal rats at approximately 2 weeks
and 2 months after subretinal or intravitreal gene transfer indi-
cated that vector spread outside the treated eye was limited (Ja-
cobson et al., 2006). RPE65-mutant dogs studied 3 months af-
ter subretinal delivery showed only sporadic vector sequences
in distal organs and no consistent pattern of dissemination. One
dog had detectable vector sequences in one optic nerve (after
bilateral injections) and another had vector in the chiasm; the
levels were near the detection limit and were not found on re-
peat testing. Among the five dogs tested for vector sequences
in the visual pathways distal to the chiasm, there were no pos-
itive results. The present study in nonhuman primates under
GLP conditions extends these observations with short-term and
3-month vector biodistribution data at the two highest doses
used in the dog studies. By 1 week after subretinal injection,
there are high levels of detectable vector sequences in the retina
and also in the vitreous, with lesser levels in the intraorbital op-
tic nerve. Distal to the optic nerve, there was only isolated de-
tection of vector sequences (mainly near the limit of detection)
and these were not apparently related to vector dose or vector
level in the retina. Non-ocular dissemination was not observed.
The longer term study of 3 months was almost devoid of de-
tectable vector sequences in both non-ocular distal tissues and
the visual pathways whether the vector administration was sub-
retinal or intravitreal. Pertinent to concerns about germ line
transmission, based on previous studies of AAV2 (reviewed in
Couto, 2004), vector genomes were not detected in the gonads
of female or male vector-treated animals, indicating that in a
nonhuman primate and at the doses used in this study, the risk
is minimal. There are no other published studies of nonhuman
primates with ocular injections specifically of rAAV-2/2.
RPE65. Two macaques (Macaca fascicularis) with subretinal
rAAV-2/4.CMV.gfp were studied for biodistribution; one was
killed 2 months postinjection and the other was biopsied
(Provost et al., 2005). Vector sequences were detected in the
injected retina and optic nerve, as in our shorter term study.
The conclusion from the available biodistribution data is that
subretinal delivery of AAV-2/2.RPE65 does not lead to wide-
spread dissemination of vector DNA in a dose-dependent man-
ner. The no-observed adverse event level is 4.5  1012 vg.
Retinal toxicity was assayed by clinical eye examinations,
ERG, and retinal histopathology with morphometry. There was
no evidence for toxicity beyond the effects expected from the
retinal surgical procedure. The histopathological data in the
nonhuman primate retina after subretinal injection challenges
our conclusion from the RPE65-mutant dog that higher doses
of subretinal rAAV-2/2.RPE65 may be threatening to retinal in-
tegrity. This may permit consideration of dose escalation in hu-
mans to at least 1.5  1012 vg. The literature describes sub-
retinal delivery of rAAV-2/4.CMV.gfp in one macaque (M.
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FIG. 5. Retinal morphometry of monkeys at 3 months postin-
jection of rAAV-2/2.RPE65 vector. Measurements are of the
outer (photoreceptor) nuclear layer thickness at three locations:
through the fovea (A), in the temporal retina (B), and in the
nasal retina (C). Shaded circles are the approximate area cov-
ered by the subretinal injection. Circles, eyes with subretinal
injections; squares, intravitreal injections (the two different
doses of rAAV-2/2.RPE65 are depicted as gray, 1, or black,
3); diamonds, control eyes with subretinal vehicle-only in-
jections. I, inferior; S, superior retina; C, center (level of the
fovea). Bars represent means 	 2 SD limits for measurements
made at corresponding locations on the control (LE) eyes.
We performed a series of dose-efficacy and safety experiments
in dogs and rats for rAAV-2/2.RPE65 (Jacobson et al., 2006)
as a step toward a human trial of gene transfer in patients with
blindness caused by mutations in the RPE65 gene (Jacobson et
fascicularis) and this experiment indicated long-term (18
months) transgene expression and no obvious interocular dif-
ference in ERGs between treated and untreated eyes. Clinical
eye examinations performed in other monkeys at shorter inter-
vals after such subretinal injections showed transgene expres-
sion but no ocular inflammation; ocular histopathology was not
reported (Le Meur et al., 2005).
Foveal analyses with in vivo microscopy in human LCA pa-
tients with RPE65 mutations showed disproportionately greater
photoreceptor layer thickness than cone photoreceptor function,
a finding consistent with the visual cycle abnormality in this
disease (Jacobson et al., 2005). Theoretically, even in late stages
of the disease, patients with measurable foveal structure could
benefit from gene transfer, even if targeted exclusively to this
retinal region. Experience with other retinal degenerative dis-
eases that lead to loss of peripheral and rod photoreceptor-me-
diated vision, such as forms of retinitis pigmentosa (Kennan et
al., 2005), indicates that even a small island of retained cone-
mediated vision can allow patients to maintain more indepen-
dence and quality of life than without this function (Szlyk et
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TABLE 3. DETECTION OF rAAV VECTOR SEQUENCES BY PCR IN NONHUMAN PRIMATE TISSUE SAMPLES: 
STUDY II, 3-MONTH DURATION
M7a M8 M9 M10 M11 M12 M13 M14 M15 M16 M17
0b/SRc 0/SR 0/SR 1/SR 1/SR 1/SR 3/SR 3/SR 3/SR 1/IV 3/IV
Non-ocular tissues
Heart — — — — — — — — — — —
Lung nd nd — — — — — — — (534) —
Liver — — — — — — — — — — —
Pancreas — — — — — — — — — — —
Spleen — — — — — — — — — — —
Kidney — — — — — — — — — — —
Jejunum — — — — — — — — — — —
Gonads — — — — — — — nd — — —
Skeletal muscle — — — — — — — — — — —
Lymph nodes
Preauricular — — — — — — — — — — —
Mandibular — — — — — — — — — — —
Tracheobronchial — nd — — — — — — — — —
Mesenteric — — — — — — — — — — —
Eye and orbit (L)
Optic nerve (L) — — — — — — — — — — —
Orbital tissue (L) — — — — — — — — — — —
Eye and orbit (R)
Optic nerve (R) — — — — — — — — — — —
Orbital tissue (R) — — — — — — — — — — —
Optic chiasm — — — — — — — — — — —
Visual pathways (L brain)
Optic tract (L) — — — — — — — — — — —
LGN (L) — — — — (126) — — — — — —
Optic radiation (L) — — — — — — — — — — —
Visual cortex (L) — — — — — — — — — — —
Superior colliculus (L) — — — — — — — — — — —
Visual pathways (R brain)
Optic tract (R) — — — — — — — nd — — —
LGN (R) — — — — — — — — — — —
Optic radiation (R) — — — — — — — — — — —
Visual cortex (R) — — — — — — — — — — —
Superior colliculus (R) — — — — — — — — — — —
Brain samples (other)
Thalamus (L) — — — — — — — — — — —
Thalamus (R) — — — — — — — — — — —
Cerebellum — — — — — — — — — — —
Abbreviations: L, left; R, right; —, no PCR amplification; PCR amplification of vector sequences:  (replicated value shown
is average, copy number per microgram of genomic DNA); 	 (single replicate value only, copy number per microgram of ge-
nomic DNA); na, not available (not determinable because of an unacceptable spike-in); nd, not done; LGN, lateral geniculate nu-
cleus.
aAnimal no.
bVector dose, relative per Table 1.
cRoute of ocular delivery: subretinal (SR), intravitreal (IV).
al., 1998). The results of the present study suggest that the pro-
cedure to deliver genetic material to the central retina may be
worth advancing, so as to decrease the chance of foveal injury
by retinal detachment and not compromise the potentially pos-
itive effects of treatment. A nontraumatic method should be
sought to deliver genetic material to the fovea, which is anatom-
ically specialized with far less thickness and less cellular ele-
ments than surrounding retina and no retinal blood supply (Pro-
vis et al., 2005).
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